In8 Bio, Inc. INAB
We take great care to ensure that the data presented and summarized in this overview for IN8BIO, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INAB
View all-
Bios Capital Management, LP Fort Worth, TX8.6MShares$1.46 Million2.31% of portfolio
-
Aigh Capital Management LLC Baltimore, MD6.19MShares$1.05 Million0.68% of portfolio
-
Franklin Resources Inc San Mateo, CA5.7MShares$968,3540.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL5.06MShares$860,7590.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$242,0620.0% of portfolio
-
683 Capital Management, LLC New York, NY750KShares$127,5000.01% of portfolio
-
Sigma Planning Corp Ann Arbor, MI701KShares$119,1150.0% of portfolio
-
Geode Capital Management, LLC Boston, MA515KShares$87,5820.0% of portfolio
-
Stonegate Investment Group, LLC Birmingham, AL180KShares$30,6000.0% of portfolio
-
Jane Street Group, LLC New York, NY116KShares$19,7060.0% of portfolio
Latest Institutional Activity in INAB
Top Purchases
Top Sells
About INAB
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Insider Transactions at INAB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Oct 04
2024
|
William Tai Wei Ho PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
126,582
+4.73%
|
-
|
|
Oct 04
2024
|
Peter C. Brandt |
BUY
Grant, award, or other acquisition
|
Direct |
253,164
+32.85%
|
-
|
|
Oct 04
2024
|
Alan S. Roemer |
BUY
Grant, award, or other acquisition
|
Direct |
126,582
+30.75%
|
-
|
|
Oct 04
2024
|
Patrick Mc Call CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,316
+32.71%
|
-
|
|
Oct 04
2024
|
Kate Rochlin Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,316
+37.13%
|
-
|
|
Dec 13
2023
|
Alan S. Roemer |
BUY
Grant, award, or other acquisition
|
Direct |
102,459
+39.27%
|
-
|
|
Dec 13
2023
|
Corinne Epperly |
BUY
Grant, award, or other acquisition
|
Direct |
81,967
+50.0%
|
-
|
|
Dec 13
2023
|
Jeremy R. Graff |
BUY
Grant, award, or other acquisition
|
Direct |
2,049
+31.05%
|
-
|
|
Dec 13
2023
|
Trishna Goswami Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,098
+37.85%
|
-
|
|
Dec 13
2023
|
Kate Rochlin Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,295
+41.19%
|
-
|
|
Dec 13
2023
|
Patrick Mc Call CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,492
+43.37%
|
-
|
|
Dec 13
2023
|
William Tai Wei Ho PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
81,967
+3.27%
|
-
|
|
Dec 13
2023
|
Peter C. Brandt |
BUY
Grant, award, or other acquisition
|
Direct |
81,967
+23.66%
|
-
|
|
Dec 13
2023
|
Lawrence Lamb EVP and CSO |
BUY
Grant, award, or other acquisition
|
Direct |
1,639
+1.59%
|
-
|
|
Sep 13
2023
|
Jeremy R. Graff |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
$0
$0.95 P/Share
|
|
Aug 25
2023
|
Patrick Mc Call CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
1,000
+13.77%
|
$1,000
$1.03 P/Share
|
|
Aug 24
2023
|
William Tai Wei Ho PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
23,800
+1.01%
|
$23,800
$1.05 P/Share
|
|
Jul 28
2023
|
Emily Fairbairn |
SELL
Other acquisition or disposition
|
Indirect |
4,111,958
-100.0%
|
-
|
|
Dec 12
2022
|
Leslie W. Kreis > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
75,001
+1.51%
|
$150,002
$2.48 P/Share
|
|
Dec 12
2022
|
Aaron G.L. Fletcher > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
75,001
+1.51%
|
$150,002
$2.48 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 557K shares |
|---|